Lifeboat Foundation

Hayley Harrison sent me this video taken-filmed by Andrés Grases and posted it to Youtube… I know for a certainty that Gene therapy will not increase Life span into 125 or beyond years due to the Animal Eukartyotic cell of the earth having a plague that infects all cells into mutation and early cell death.

This year I had the privilege to record in full Liz Parrish talk delivered at RAADfest 2019 (Revolution Against Aging and Death Festival 2019), which took place in Las Vegas, NV from 3 to 6 of October.

Continue reading “Liz Parrish conference at RAADfest 2019 (05-Oct-2019)” »

Say this about the kinds of molecular mayhem that we know underlie aging: Mechanisms like whether the ends of chromosomes fray (bad) and whether genes’ on-off status breaks down (really bad) at least sound like plausible ways to impair vital organs, from skin to brains and hearts, and produce the whole sorry mess known as aging.

On Wednesday, scientists reported a driver of aging that, in contrast, even the lead researcher diplomatically calls “counterintuitive”: neuronal activity. Aging, of course, affects the brain. But the brain seems to affect aging, too, they found: In creatures from worms to mice to people, high levels of neuronal firing spell a shorter life span. Lower levels — naturally, or due to drugs that dampen neurons’ activity — increase longevity.

The discovery⁴ was so surprising that it’s taken two years to be published (in Nature) because of how much additional data the outside scientists reviewing the study requested. Geneticist Bruce Yankner of Harvard Medical School, who led the research, understood their skepticism. “If you say you have a cat in your backyard, people believe you,” he said. “If you say you have a zebra, they want more evidence.”

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.

Huda Suliman of Icaria Life Sciences discussed her company’s role in the rejuvenation biotechnology ecosystem, including small molecule drug discovery and drug screening along with how her company deals with irreproducibility in the scientific literature. She explained how species differences are an issue, and she explained the differences between aging-focused and traditional medical research.

After almost two years mired in extensive peer review, a landmark new study just published in the prestigious journal Nature is strongly associating excessive neural activity with shorter lifespans. The study suggests a protein known to suppress neural excitation affects a number of longevity pathways, effectively slowing the aging process.

The impressive research started several years ago with a gene expression study of post-mortem human brain tissue from hundreds of subjects. All the subjects were cognitively normal at the time of death. Bruce Yankner, senior author on the new study, says one thing quickly stood out to his team – the longer a person lived, the lower their expression of genes connected to neural excitement.

More specifically, the researchers identified upregulation of a protein called REST in the brains of those longest-lived subjects. REST first came to the attention of the research team back in 2014. The protein’s role in the brain was generally thought to only play a part in prenatal neurodevelopment, regulating the expression of genes in a developing brain.

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.

John Lewis of Oisin Biotechnologies discussed senolytics, which are drugs that kill senescent cells. He explained the differences between healthy and senescent cells along with the senescence-associated secretory phenotype (SASP) responsible for systemic inflammation. He went into detail about senolytics and what his company looks for when creating them, including details about suicide genes and biomarkers of senescence. He also discussed issues with bringing these drugs to humans and suggested oncology as a possible method for bringing them to the clinic.

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.

James Peyer of Kronos BioVentures gave a talk about the investment aspects of rejuvenation biotechnology, first explaining the effects of the population pyramid, showing the audience why cures for age-related diseases are such a necessity, and comparing population projections. He explained the startup ecosystem in biotechnology, drug approval, and IPO prices for nascent biotechnology companies. Finally, he explained the financial issues facing startup biotechnology companies and his company’s role in helping these companies achieve their goals.

If you’ve ever worked with a virtualized computer, or played a video game ROM from a long-defunct console on your new PC, you understand the concept already: a mind is simply software, and the brain, the hardware it runs on. Imagine a day when your neurons, the matter that forms your mind, are transferred to a machine and their counterparts in your skull are disabled.

Are you still you? Imagine a future of mind uploading, whole-brain emulation, and the full understanding of the connectome. Now, imagine neuroscientists even discover a way to resurrect the dead, to upload the mind of those who have gone before, our ancestors, Socrates, Einstein?

In a paper published in Plos One in early December, scientists detailed how they were able to elicit a pattern similar to the living condition of the brain when exposing dead brain tissue to chemical and electrical probes. Authors Nicolas Rouleau, Nirosha J. Murugan, Lucas W. E. Tessaro, Justin N. Costa, and Michael A. Persinger (the same Persinger of the God-Helmet studies) wrote about this breakthrough.